Review Article
Rituximab-Based Treatment, HCV Replication, and Hepatic Flares
Table 1
Studies on rituximab-based chemotherapy that investigated both HCV reactivation and hepatic flares.
| |
Coppola et al., 2012 [40] | Ennishi et al., 2010 [36] | Marignani et al., 2011 [39] | Pitini et al., 2010 [38] | Tsutsumi et al., 2009 [37] |
| Type of study | Observational prospective | Multicentre retrospective | Observational retrospective | Observational prospective | Observational prospective | Disease | LNH, CLL | LNH (DLBCL) | LNH | LNH (DLBCL, FL) | LNH (DLBCL) |
Number of cases | 8 | 34 | 3 | 10 | 4 | Treatment | R-CHOP in 5 | R- and P-based | R-CHOP | RCHOP | R-CHOP in 1 | | R-FC in 1 | chemotherapy | | | R-CHO in 2 | | CP and then R-FC | | | | R-THP-CO in 1 | | in 1 | | | | | | FC in 1 | | | | | With HCV reactivation, number of cases: | 7 | 34 | 2 | 10 | 4 | During CT | 7 | 34 | 0 | 10 | 4 | After CT | 0 | 0 | 2 | 0 | 0 | With hepatic flare, number of cases: | 7 |
The available datum (27%) refers to flares observed in 131 patients, of whom only 34 were followed up for HCV RNA | 2 | 10 | 3 | During CT | 7 | 0 | 10 | 3 | After CT | 0 | 2 | 0 | 0 | | | | | | | | | | | | | | | |
|
|
NHL: non-Hodgkin lymphoma; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; CLL: chronic lymphocytic leukaemia; R-CHO: rituximab, cyclophosphamide, doxorubicin, vincristine; RFC: rituximab, fludarabine, and cyclophosphamide; CP: cyclophosphamide, prednisone; FC: fludarabine and cyclophosphamide; R-THPCOP: rituximab, pirarubicin (tetrahydropyranyl-adriamicin [TPH] ) cyclophosphamid, vincristine without prednisone.
|